An Expert Opinion on the Role of the Rosuvastatin/Amlodipine Single Pill Fixed Dose Combination in Cardiovascular Prevention

Overview

Journal High Blood Press Cardiovasc Prev

Specialty Cardiology & Vascular Diseases

Date 2023 Apr 5

PMID 37020154

Authors

Giovanna Gallo

Riccardo Sarzani

Arrigo Francesco Giuseppe Cicero

Stefano Genovese

Matteo Pirro

Luca Gallelli

Andrea Faggiano

Massimo Volpe

Affiliations

Soon will be listed here.

Abstract

Current cardiovascular disease prevention strategies are based on the management of cardiovascular risk as a continuum, redefining the therapeutic goals for each individual based on the estimated global risk profile. Given the frequent clustering of the principal cardiovascular risk factors, such as hypertension, diabetes and dyslipidaemia, in the same individual, patients are required to take multiple drugs to achieve therapeutic targets. The adoption of single pill fixed dose combinations may contribute to achieve better control of blood pressure and cholesterol compared to the separate administration of the individual drugs, mostly due to better adherence related to therapeutic simplicities. This paper reports the outcomes of an Expert multidisciplinary Roundtable. In particular, the rational and potential clinical use of the single pill fixed dose combination "Rosuvastatin-Amlodipine" for the management of concomitant hypertension/hypercholesterolemia in different clinical fields are discussed. This Expert Opinion also illustrates the importance of an early and effective management of total cardiovascular risk, highlights the substantial benefits of combining blood pressure and lipid-lowering treatments in a single-pill fixed dose combination and attempts to identify and overcome the barriers to the implementation in clinical practice of the fixed dose combinations with dual targets. This Expert Panel identifies and proposes the categories of patients who may benefit the most from this fixed dose combination.

References

Volpe M, Gallo G, Tocci G . Is early and fast blood pressure control important in hypertension management?. Int J Cardiol. 2017; 254:328-332. DOI: 10.1016/j.ijcard.2017.12.026. View

Nissen S, Nicholls S, Sipahi I, Libby P, Raichlen J, Ballantyne C . Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006; 295(13):1556-65. DOI: 10.1001/jama.295.13.jpc60002. View

Adams S, Alaeiilkhchi N, Wright J . Pitavastatin for lowering lipids. Cochrane Database Syst Rev. 2020; 6:CD012735. PMC: 7387421. DOI: 10.1002/14651858.CD012735.pub2. View

Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G . Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2010; 29(3):610-8. DOI: 10.1097/HJH.0b013e328342ca97. View

Arnett D, Blumenthal R, Albert M, Buroker A, Goldberger Z, Hahn E . 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 74(10):e177-e232. PMC: 7685565. DOI: 10.1016/j.jacc.2019.03.010. View

Jones P, Davidson M, Stein E, Bays H, McKenney J, Miller E . Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003; 92(2):152-60. DOI: 10.1016/s0002-9149(03)00530-7. View

. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736-1788. PMC: 6227606. DOI: 10.1016/S0140-6736(18)32203-7. View

Kim W, Chang K, Cho E, Ahn J, Yu C, Cho K . A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension. J Clin Hypertens (Greenwich). 2020; 22(2):261-269. PMC: 8029832. DOI: 10.1111/jch.13774. View

Osterloh I . An update on the safety of amlodipine. J Cardiovasc Pharmacol. 1991; 17 Suppl 1:S65-8. DOI: 10.1097/00005344-199117001-00020. View

10.

Castellano J, Pocock S, Bhatt D, Quesada A, Owen R, Fernandez-Ortiz A . Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022; 387(11):967-977. DOI: 10.1056/NEJMoa2208275. View

11.

Herttua K, Martikainen P, Batty G, Kivimaki M . Poor Adherence to Statin and Antihypertensive Therapies as Risk Factors for Fatal Stroke. J Am Coll Cardiol. 2016; 67(13):1507-1515. PMC: 4863178. DOI: 10.1016/j.jacc.2016.01.044. View

12.

Sarzani R, Laureti G, Gezzi A, Spannella F, Giulietti F . Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient. Ther Adv Chronic Dis. 2022; 13:20406223221102754. PMC: 9235298. DOI: 10.1177/20406223221102754. View

13.

Perez-Calahorra S, Laclaustra M, Marco-Benedi V, Pinto X, Sanchez-Hernandez R, Plana N . Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence. Lipids Health Dis. 2019; 18(1):216. PMC: 6905000. DOI: 10.1186/s12944-019-1153-x. View

14.

Spannella F, Filipponi A, Giulietti F, Di Pentima C, Bordoni V, Sarzani R . Statin therapy is associated with better ambulatory blood pressure control: a propensity score analysis. J Hypertens. 2019; 38(3):546-552. DOI: 10.1097/HJH.0000000000002276. View

15.

Volpe M, Erhardt L, Williams B . Managing cardiovascular risk: the need for change. J Hum Hypertens. 2007; 22(2):154-7. DOI: 10.1038/sj.jhh.1002273. View

16.

Adams S, Sekhon S, Wright J . Lipid-lowering efficacy of rosuvastatin. Cochrane Database Syst Rev. 2014; (11):CD010254. PMC: 6463960. DOI: 10.1002/14651858.CD010254.pub2. View

17.

Stalenhoef A, Ballantyne C, Sarti C, Murin J, Tonstad S, Rose H . A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J. 2005; 26(24):2664-72. DOI: 10.1093/eurheartj/ehi482. View

18.

Castilla-Guerra L, Fernandez-Moreno M, Leon-Jimenez D, Rico-Corral M . Statins in Ischemic Stroke Prevention: What Have We Learned in the Post-SPARCL (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels) Decade?. Curr Treat Options Neurol. 2019; 21(5):22. DOI: 10.1007/s11940-019-0563-4. View

19.

Cosentino F, Grant P, Aboyans V, Bailey C, Ceriello A, Delgado V . 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 41(2):255-323. DOI: 10.1093/eurheartj/ehz486. View

20.

Gupta A, Mackay J, Whitehouse A, Godec T, Collier T, Pocock S . Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018; 392(10153):1127-1137. DOI: 10.1016/S0140-6736(18)31776-8. View